The platforms will enable the company to progress its customer’s complex biologic drug programs towards clinical trials while de-risking the journey to Investigational New Drug (IND) application.
Matthew Stober, CEO at Abzena, said: “The higher productivity that’s achievable with the AbZelect and AbZelectPRO platforms means we can produce more drug substances per manufacturing run.
“These efficiencies will not only expand our capacity and help to reduce the cost of goods for our customers but also reduce the time it takes to get new and critical therapies to patients in need.”
Both platforms will enable the generation and selection of high-yielding mammalian CHO cell lines for therapeutic protein and recombinant vaccine production.
Designed for traditional protein programs, such as antibodies, AbZelect is optimized across the three key areas of vector, host cell line, and process. It also provides improved cell doubling times, viable cell densities, and robust and stable cell lines.
In addition, AbZelectPRO combines AbZelect with ProteoNic's 2G UNic vector technology.
This combination boosts expression levels and generates higher producing, stable cell lines expressing proteins including bispecifics, fusion proteins, and other novel modalities, the company said.
According to Abzena, by streamlining the CLD process, these platforms reduce timelines from DNA to research cell banks to 15 weeks with ‘exceptional’ productivity levels.
They can also provide cost efficiencies and optionality to de-risk biologics development, including rapid production of material, tech transfer, scale up and manufacture.